Compare ELF & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELF | PTCT |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.5B |
| IPO Year | 2016 | 2006 |
| Metric | ELF | PTCT |
|---|---|---|
| Price | $111.51 | $60.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 15 |
| Target Price | ★ $114.94 | $97.80 |
| AVG Volume (30 Days) | ★ 1.2M | 946.0K |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ 1.12 | 0.34 |
| Revenue | ★ $1,636,472,000.00 | $264,734,000.00 |
| Revenue This Year | $20.90 | N/A |
| Revenue Next Year | $8.85 | $8.55 |
| P/E Ratio | $101.21 | ★ $71.73 |
| Revenue Growth | 24.59 | ★ 36.19 |
| 52 Week Low | $48.82 | $58.80 |
| 52 Week High | $123.07 | $90.87 |
| Indicator | ELF | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 43.39 |
| Support Level | $90.39 | $58.80 |
| Resistance Level | $118.29 | $63.74 |
| Average True Range (ATR) | 4.02 | 2.31 |
| MACD | -0.37 | 0.34 |
| Stochastic Oscillator | 43.62 | 30.89 |
e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.